Key result
Preprocedural severe CKD did not modify the impact of postprocedural AKI in predicting 30-day (Pint=0.129) and 1-year (Pint=0.386) mortality after transcatheter aortic valve implantation.
Why the study?
The impact of severe chronic kidney disease on the relationship between acute kidney injury and mortality after transcatheter aortic valve implantation was unclear.
Does preprocedural severe CKD modify the impact of postprocedural AKI on mortality in patients undergoing TAVI?
Cohort (n=2,733)
Yes
Does preprocedural severe CKD modify the impact of postprocedural AKI on mortality in patients undergoing TAVI?
Preprocedural severe CKD does not modify the negative impact of postprocedural AKI on early and mid-term mortality after TAVI, highlighting the need for AKI prevention strategies in all patients regardless of baseline renal function.
Aims We aim at exploring whether severe chronic kidney disease (CKD) may modify the impact of acute kidney injury (AKI) post‐transcatheter aortic valve implantation (TAVI) on early, mid, and long‐term mortality. Methods and results The analysis included 2,733 TAVI patients from the Italian Clinical Service Project. The population was stratified in four groups according to the presence of baseline severe CKD and postprocedural AKI. All‐cause mortality was the primary end point. Postprocedural AKI is associated with an increased risk of early and mid‐term mortality after TAVI regardless of baseline severe CKD. Preprocedural severe CKD is associated with an increased risk of long‐term mortality after TAVI regardless of postprocedural AKI. No interaction between preprocedural severe CKD and postprocedural AKI was observed in predicting mortality at both 30‐day (CKD: hazard ratio [HR] = 2.65, 95% confidence interval [CI] = 1.15–6.12; no‐CKD: HR = 3.83, 95% CI = 2.23–6.58; Pint = .129) and 1‐year (CKD: HR = 2.29, 95% CI = 1.37–3.82; no‐CKD: HR = 2.47, 95% CI = 1.75–3.49; Pint = .386). Preprocedural severe CKD is an independent predictor of postprocedural AKI (HR = 2.17, 95% CI = 1.56–3.03; p < .001) as well as general anesthesia and access alternative to femoral. Among no‐AKI patients, those with severe CKD at admission underwent kidney function recovery after TAVI (serum creatinine at baseline 2.24 ± 1.57 mg/dL and at 48‐hr 1.80 ± 1.17 mg/dL; p = .003). Conclusions Preprocedural severe CKD did not modify the impact of postprocedural AKI in predicting early and mid‐term mortality after TAVI. Closely monitoring of serum creatinine and strategies to prevent AKI post‐TAVI are needed also in patients without severe CKD at admission.
No takes yet. Share an insight, caveat, or question.
Adamo et al. (2020) conducted a cohort in Transcatheter aortic valve implantation (TAVI) (n=2,733). Postprocedural acute kidney injury (AKI) vs. No postprocedural AKI was evaluated on All-cause mortality (HR 2.65, 95% CI 1.15-6.12, p=0.129). Preprocedural severe CKD did not modify the impact of postprocedural AKI in predicting 30-day (Pint=0.129) and 1-year (Pint=0.386) mortality after transcatheter aortic valve implantation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: